Fifth US Biosimilar To Herceptin Launched By Merck
Ontruzant Biosimilar Available For All Eligible Indications
Merck & Co has launched Ontruzant, the trastuzumab biosimilar developed and manufactured by Samsung Bioepis, in the US following a staggered approval process and earlier intellectual-property hurdles. The list price discount offered by the firm puts it in the middle of the pack among the four other biosimilar players currently on the market.
